Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350701 · ClinicalTrials.gov registry record · Phase 4
Effect of Androgel on Type 2 Diabetic Males With Hypogonadism
A Phase 4 study, sponsored by University at Buffalo.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
NCT00350701: Completed Phase 4 study, sponsored by University at Buffalo.
NCT00350701 is a Phase 4 study that has completed, run by University at Buffalo. The registered enrollment target is 49 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00350701, a Phase 4 study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is to study the effect of replacing testosterone on different inflammatory cells in type 2 diabetics with low testosterone levels.
Primary Outcome
To measure the percent change from baseline at 8 weeks in Nuclear Factor kB DNA binding activity (in arbitrary units normalized to 100% at baseline) between AndroGel and Placebo using electrophoretic mobility shift assay (EMSA). Values at 8 weeks are converted to percent change and compared between the groups
Interventions
- DRUG placebo
- DRUG androgel
- DRUG androgel 10g
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2006-07 |
| Est. Completion | 2013-07 |
| Phase | Phase 4 |
What the finished NCT00350701 record still lists
NCT00350701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00350701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00350701 about?
NCT00350701 is a clinical study titled "Effect of Androgel on Type 2 Diabetic Males With Hypogonadism". This is to study the effect of replacing testosterone on different inflammatory cells in type 2 diabetics with low testosterone levels.
What is the current status of trial NCT00350701?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2006-07. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00350701?
The interventions under investigation include: placebo (DRUG), androgel (DRUG), androgel 10g (DRUG).
Who is sponsoring clinical trial NCT00350701?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00350701's enrollment target sits among peer trials
49 1323rd of 2000 higher than 670 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia